The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALC | -18.98% | +24.33% | +4.45% | +33% |
| S&P | +14.5% | +93.32% | +14.09% | +133% |
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.
The switch will increase the availability of pain and allergy drugs from GlaxoSmithKline and Alcon.
The growing eye industry is something investors can’t ignore.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.60B | 4.0% |
| Gross Profit | $1.39B | 1.0% |
| Gross Margin | 53.47% | -1.6% |
| Market Cap | $43.66B | -0.6% |
| Market Cap / Employee | $1.71M | 0.0% |
| Employees | 25.6K | 1.1% |
| Net Income | $176.00M | -21.1% |
| EBITDA | $602.00M | -5.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.41B | 2.6% |
| Accounts Receivable | $1.99B | 8.9% |
| Inventory | 2.4K | 2.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.10B | 4.5% |
| Short Term Debt | $157.00M | -24.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.51% | -0.2% |
| Return On Invested Capital | 1.66% | 1.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $403.00M | -8.0% |
| Operating Free Cash Flow | $505.00M | -4.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 42.52 | 41.19 | 41.55 | 40.67 | 1.72% |
| Price to Book | 2.36 | 1.96 | 2.18 | 1.99 | -5.95% |
| Price to Sales | 5.10 | 4.26 | 4.72 | 4.38 | -4.87% |
| Price to Tangible Book Value | 15.20 | 11.25 | 11.68 | 12.71 | -14.05% |
| Price to Free Cash Flow TTM | 38.15 | 28.66 | 30.76 | 30.24 | -26.52% |
| Enterprise Value to EBITDA | 82.41 | 65.55 | 64.03 | 79.37 | 4.97% |
| Free Cash Flow Yield | 2.6% | 3.5% | 3.3% | 3.3% | 36.10% |
| Return on Equity | 5.6% | 4.8% | 5.2% | 5.0% | -7.55% |
| Total Debt | $5.12B | $5.14B | $5.20B | $5.26B | 3.36% |
ALC earnings call for the period ending September 30, 2021.
ALC earnings call for the period ending June 30, 2021.
ALC earnings call for the period ending March 31, 2021.
ALC earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
